SHENZHEN, China, and REDWOOD CITY, California, May 4, 2015 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced today that it has expanded its relationship with BGI, the world's largest genomics organization, to provide QIAGEN's Ingenuity(R) Variant Analysis(TM) in integrated bioinformatics for all customers of BGI's sequencing services.

Under the reseller agreement, BGI customers will receive sequencing data generated from their samples through Ingenuity Variant Analysis' secure, cloud-based environment and gain access to its leading comprehensive gene variant data and genomic interpretation applications. BGI will provide Ingenuity Variant Analysis to customers in China, Hong Kong and Taiwan, with plans to expand to other regions throughout the year. BGI collaborates with more than 10,000 organizations and 30,000 partners worldwide, providing sequencing services for thousands of research projects, including large-scale genome initiatives.

"We are very pleased to expand QIAGEN's relationship with BGI, the global leader in sequencing services. Integrating Ingenuity Variant Analysis into BGI's highly reliable sequencing services will enable clients to accelerate workflows. They'll be able to transform large quantities of genomic data into valuable molecular insights for research or clinical applications," said Laura Furmanski, Head of QIAGEN's Bioinformatics Business Area. "Bioinformatics solutions from QIAGEN are growing rapidly as scientists and healthcare professionals increasingly use genomic information to guide research and provide precise diagnosis for medical decision-making. We are committed to working with leading organizations such as BGI to make these improvements in life possible."

Yingrui Li, Chief Scientist of BGI, said: "We welcome this opportunity to expand our relationship with QIAGEN for the benefit of BGI collaborators around the world. Coupling BGI's world-class sequencing with the deep bioinformatics of Ingenuity Variant Analysis will give researchers an enhanced, integrated way to seamlessly move quickly from raw data to valuable insights."

QIAGEN's footprint in bioinformatics continues to expand with a product portfolio that includes the Ingenuity, CLC bio and BIOBASE product lines for analysis, interpretation and reporting of biological data from next-generation sequencing (NGS). The industry-leading Ingenuity Variant Analysis software quickly filters genetic variants in a secure, cloud-based environment to identify variants most likely to cause disease, drawing upon the Ingenuity Knowledge Base, a repository of expertly curated biological interactions and functional annotations created from millions of individually modeled relationships between proteins, genes, complexes, cells, tissues, drugs, and diseases. To learn more, please visit http://www.ingenuity.com . In March 2015, QIAGEN announced a reseller agreement with GATC Biotech, a leading European provider of DNA and RNA sequencing worldwide, to provide access to Ingenuity Variant Analysis as part of GATC's sequencing services.

About BGI

BGI, founded in 1999 with the vision of using genomics to benefit the human race, is now the world's largest genomics organization. Headquartered in Shenzhen, China, BGI encompasses both private nonprofit research institutes and commercial units for sequencing applications, as well as its affiliated offshoots BGI Americas and BGI Europe. BGI has established partnerships and collaborations with leading academic and government research institutions around the world, as well as global biotechnology and pharmaceutical companies, to support a variety of healthcare, agricultural, environmental and related applications. BGI's sequencing services are powered by more than 230 DNA sequencers with a data output capability of approximately 16 terabytes per day. For more information, please visit http://www.genomics.cn.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2014, QIAGEN employed approximately 4,300 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, new product developments, new product launches, regulatory submissions, and financing plans are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). 


        
        Contacts:
        Public Relations:
        Dr. Thomas Theuringer
        Director Public Relations
        +49-2103-29-11826
        +1-240-686-7425

        Email: pr@qiagen.com

http://www.twitter.com/qiagen

https://www.facebook.com/QIAGEN

        
        Investor Relations:
        John Gilardi
        Vice President Corporate Communications and Investor Relations
        +49-2103-29-11711
        +1-240-686-2222

        Email: ir@qiagen.com
        ir.qiagen.com [http://www.qiagen.com/About-Us/Investors ]

SOURCE QIAGEN N.V.